Latest filing published 16 Aug 2022 for Epizyme, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Shefali Agarwal discloses dealings in 2 companies, chiefly Epizyme, Inc. and Fate Therapeutics Inc. In total, 14 filings cover trades dated from 2 June 2021 to 12 August 2022.
On the market, this insider has only sold: 7 sales, €49k in total. The totals do not cover 1 filing with an undisclosed amount. Besides market trades, the filings include 4 share grants and 1 option exercise. Since January 2022: no purchases and 6 sales on the market.
The latest filing, published on 16 August 2022, reports a transaction in Epizyme, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations